Company
Headquarters: Paris, France
Employees: 7
CEO: Dr. Jean-Philippe Milon
€3.5 Million
EUR as of Jan. 1, 2024
US$3.9 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $461.52 B |
Vertex Pharmaceuticals Incorporated | $107.23 B |
Regeneron Pharmaceuticals, Inc. | $100.01 B |
CSL Limited | $94.74 B |
Marinomed Biotech AG | $73.23 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension; and in Phase IIb clinical trial for heart failure. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company was founded in 2005 and is based in Paris, France.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Quantum Genomics SA has the following listings and related stock indices.
Stock: XSTU: 2QG wb_incandescent
Stock: Euronext: ALQGC wb_incandescent
Stock: FSX: 2QG wb_incandescent